COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

bioRxiv posts many COVID19-related papers. A reminder: they have not been formally peer-reviewed and should not guide health-related behavior or be reported in the press as conclusive.

29,927 Articles (22,054 medRxiv, 7,873 bioRxiv)

Most recent first Previous |  Page 190: Articles 1891-1900  | Next

SARS-CoV-2 lineage-specific disease symptoms and disease severity in Sao Caetano do Sul city, Brazil
Sales, F. C. S., Prete, C. A., Abade, L., Buss, L. F., Candido, D. S., Claro, I. M., Moreira, F. R. R., Manulli, E. R., Capuani, L., Silva, C. A. M., Oliveira, B. A., Coletti, T., Paiao, H. G. O., Costa, S. F., Correa, M. C. M., Leal, F. E., Parag, K. V., Nascimento, V. H., Faria, N. R., Sabino, E. C.
10.1101/2023.10.19.23297252 — Posted: 2023-10-20
Excess deaths in China during SARS-CoV-2 viral waves in 2022-2023
Jha, P., Brown, P. E., Lam, T., Morawski, E., Reid, A.
10.1101/2023.10.18.23297204 — Posted: 2023-10-19
XAV-19 a Glyco-Humanized polyclonal antibody targeting SARS-CoV-2 accelerates the recovery of mild to moderate COVID-19 patients and keeps its neutralizing activity against Omicron and its subvariants.
Poulakou, G., Royer, P.-J., Evgeniev, N., Evanno, G., Shneiker, F., Marcelin, A.-G., Vanhove, B., Duvaux, O., Marot, S., Calvez, V.
10.1101/2023.10.09.23296726 — Posted: 2023-10-19
Association between common adverse events after COVID-19 vaccination and anti-SARS-CoV-2 antibody concentrations in a population-based prospective cohort study in the Netherlands
Holwerda, M. R., Hoeve, C. E., Huiberts, A. J., den Hartog, G., de Melker, H. E., van den Hof, S., Knol, M.
10.1101/2023.10.19.23297194 — Posted: 2023-10-19
COVID-19 cases associated with testing policies in 34 highly democratic countries, 2020-2022
Robertson, L. S.
10.1101/2023.10.19.23297270 — Posted: 2023-10-19
Th2 and Th17-Associated Immunopathology Following SARS-CoV-2 Breakthrough Infection in Spike-vaccinated ACE2-humanized Mice
Zhang, T., Magazine, N., McGee, M. C., Carossino, M., Veggiani, G., Kousoulas, K. G., August, A., Huang, W.
10.1101/2023.10.18.563016 — Posted: 2023-10-19
Caveolin-1 mediates neuroinflammation and cognitive impairment in SARS-CoV-2 infection
Trevino, T. N., Fogel, A. B., Minshall, R., Richner, J. M., Lutz, S. E.
10.1101/2023.10.18.563024 — Posted: 2023-10-19
De novo generation of antibody CDRH3 with a pre-trained generative large language model
He, H., He, B., Guan, L., Zhao, Y., Chen, G., Zhu, Q., Chen, C. Y.-C., Li, T., Yao, J.
10.1101/2023.10.17.562827 — Posted: 2023-10-18
The SHOW COVID-19 cohort: methods and rationale for examining the statewide impact of COVID-19 on the social determinants of health
Schultz, A. A., Nelson-Bakkum, E., Nikodemova, M., Luongo, S., Barnet, J. H., Walsh, M. C., Bersch, A., Cadmus-Bertram, L., Engelman, C. D., Lubsen, J., Peppard, P., Sethi, A., Malecki, K. M.
10.1101/2023.10.17.23297146 — Posted: 2023-10-18
Persistent high mortality rates for Diabetes Mellitus and Hypertension after excluding deaths associated with COVID-19 in Brazil, 2020-2022
Moreira, R., Bastos, L. S., Carvalho, L. M., Freitas, L. P., Pacheco, A. G.
10.1101/2023.10.17.23297174 — Posted: 2023-10-18

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).